semaglutide cardiovascular outcomes study 2025 news Oral semaglutide found to lower risk of heart failure events in people with type 2 diabetes

🔴Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial⤵️ 🔹Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants

20.09

★★★★☆4.8 (126)

Population‐level impact of semaglutide 2.4 mg in patients with obesity or overweight and cardiovascular disease: A modelling study based on the SELECT trial - Nanna - 2025 - Diabetes, Obesity and Metabolism

27.27

★★★★★4.9 (98)

AHA Late Breaking Science: Day 1 Highlights 🫀SELECT Trial: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes ✓: ⬇️ 20% Risk of a composite of cardiovascular death ❤️, nonfatal myocardial infarction, or

24.34

★★★★★5.0 (157)

Semaglutide protects the heart beyond weight loss, SELECT trial shows

28.66

★★★★★4.7 (84)

An Observational Study of Cardiovascular Outcomes of Tirzepatide vs Glucagon-Like Peptide-1 Receptor Agonists

26.79

★★★★★4.9 (203)

VisualAbstract: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

25.36

★★★★★5.0 (176)

In patients with cardiovascular disease and overweight or obesity but no diabetes, semaglutide was superior to placebo in lowering the risk of major adverse cardiovascular events at a mean follow-up of 39.8

27.85

★★★★★4.8 (132)